LTGO Latigo Biotherapeutics, Inc.
Fundamentals / CIK 0002056611 / USDLatigo Biotherapeutics, Inc. reported $408.5M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open LTGO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$401.2M Total debt: $1.19M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $17.50M | $21.23M | -- | $22.10M | $22.92M | -- |
| Total Operating Expenses | $22.93M | $25.81M | -- | $24.72M | $25.75M | -- |
| Operating Income | -$22.93M | -$25.81M | -- | -$24.72M | -$25.75M | -- |
| EBITDA | -$22.83M | -$25.71M | -- | -$24.62M | -$25.64M | -- |
| Interest Expense | $699K | $251K | -- | $0 | $0 | -- |
| Income Tax Expense | $0 | $0 | -- | $0 | $0 | -- |
| Net Income | -$20.95M | -$25.80M | -$22.96M | -$24.80M | -$25.84M | -$20.95M |
| Basic EPS | -$0.55 | -$27.59 | -- | -$29.50 | -$36.52 | -- |
| Diluted EPS | -$0.55 | -$27.59 | -- | -$29.50 | -$36.52 | -- |
| Basic Shares Outstanding | 37.8M | 935.0K | -- | 840.4K | 707.5K | -- |
| Diluted Shares Outstanding | 37.8M | 935.0K | -- | 840.4K | 707.5K | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2025-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $401.2M | $55.00M | $69.44M |
| Cash & Short-Term Investments | $401.2M | $55.00M | $69.44M |
| Total Current Assets | $406.4M | $59.20M | $73.83M |
| Property, Plant & Equipment, Net | $440K | $457K | $446K |
| Other Non-Current Assets | $433K | $3.80M | $616K |
| Total Non-Current Assets | $2.01M | $5.56M | $1.69M |
| Total Assets | $408.5M | $64.76M | $75.52M |
| Accounts Payable | $5.08M | $3.57M | $5.01M |
| Total Current Liabilities | $13.96M | $51.58M | $18.45M |
| Other Non-Current Liabilities | $35K | $35K | $35K |
| Total Non-Current Liabilities | $518K | $683K | $162K |
| Total Liabilities | $14.48M | $52.26M | $18.61M |
| Total Debt (incl. Leases) | $1.19M | $1.35M | $690K |
| Common Stock | $7.0K | $0 | $0 |
| Retained Earnings | -$312.8M | -$291.9M | -$243.1M |
| Total Stockholders' Equity | $394.0M | -$276.1M | -$231.7M |
| Total Equity | $394.0M | -$276.1M | -$231.7M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$20.95M | -$25.80M | -$22.96M | -$24.80M | -$25.84M | -$20.95M |
| Depreciation & Amortization | $100K | $100K | -- | $100K | $100K | -- |
| Stock-Based Compensation | $2.54M | $2.14M | -- | $1.82M | $1.68M | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 29.11x | 1.15x | -- | -- | -- | -- |
| Quick Ratio | 28.73x | 1.07x | -- | -- | -- | -- |
| Debt to Equity | 0.00x | -- | -- | -- | -- | -- |